US-based neurotechnology company Cognito Therapeutics has collaborated with Ochsner Health to establish the Brain Health ...

Cognito Therapeutics announced today that it entered into a collaboration with Ochsner Health to advance new approaches to ...

Cognito Therapeutics, a late clinical-stage neurotechnology company pioneering non-invasive neuroprotective therapies in ...

Discover the collaboration between Ochsner Health and Cognito Therapeutics to advance brain health innovations in New Orleans ...

Expecting pivotal data this year, the company has raised a Series C round to support the launch of a noninvasive device designed to treat brain diseases using light and sound.

With a pivotal trial readout for Cognito’s Spectris due later this year, the company anticipates launching the Alzheimer’s disease therapeutic in the US by 2027.

Cognito Therapeutics and the West Virginia University Rockefeller Neuroscience Institute (RNI), announced today the launch of the first Brain Health Collaboratory, a new model designed to accelerate ...

“If you can drive the brain's naturally occurring activity, what you can get is the biologic expression that is important for brains to maintain and protect themselves.,” CEO Christian Howell explains ...

Cognito Therapeutics, a pioneering neurotechnology company developing disease-modifying therapies for neurodegenerative diseases, today announced new data from its OVERTURE feasibility trial at the AD ...

Christian Howell, CEO of Cognito Therapeutics, sits down with Nasdaq’s Kristina Ayanian to discuss the company’s breakthrough approach to treating Alzheimer’s using light and sound stimulation. From ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Cognito Therapeutics, a clinical-stage medical device company pioneering non-invasive neuroprotection therapies against neurodegenerative diseases, today announced ...